Paper Details

  1. Home
  2. Paper Details

Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer.

Author: DawarRicha, DrusboskyLeylah M, IkpeazuChukwuemeka V, RodriguezEstelamari

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

MET Exon 14 skipping mutation inhibitors, such as capmatinib and tepotinib, have shown significant clinical activity in treating lung cancer patients with this mutation. While these inhibitors can cross the blood-brain barrier, acquired resistance remains a challenge.
Paper Details　
Original Abstract of the Article :
METex14 skipping mutations occur in about 3-4% of lung adenocarcinoma patients and 1-2% of patients with other lung cancer histology. The MET receptor tyrosine kinase and its ligand hepatocyte growth factor (HGF) are established oncogenic drivers of NSCLC. A mutation that results in loss of exon 14 ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381548/

データ提供：米国国立医学図書館（NLM）

Therapeutic Strategies in METex14 Skipping Mutated Non-Small Cell Lung Cancer

The field of [non-small cell lung cancer (NSCLC) treatment] is continuously seeking new and targeted therapies to combat this deadly disease. This review article focuses on [METex14 skipping mutations], a specific genetic alteration that occurs in a subset of NSCLC patients. The authors discuss the [role of MET inhibition] in treating these patients and highlight the [efficacy and safety] of several [MET kinase inhibitors (TKIs)], including [capmatinib], [tepotinib], and [savolitinib]. They emphasize the importance of [early detection and targeted therapy] for maximizing patient outcomes.

METex14 Skipping Mutations: A New Frontier in Lung Cancer Treatment

This review article underscores the [importance of precision medicine] in [NSCLC treatment]. The authors highlight the discovery of [METex14 skipping mutations] as a [specific oncogenic driver] in a subset of NSCLC patients. They discuss the [development of targeted therapies] that specifically inhibit the [MET receptor tyrosine kinase], leading to promising results in clinical trials. It's like finding a hidden oasis in the desert of lung cancer, where the water is tailored to the specific needs of the thirsty traveler.

Navigating the Challenges of Targeted Therapy

The authors acknowledge the [challenges] associated with [targeted therapy], including the [development of resistance] to MET inhibitors. They call for further research to [overcome these challenges] and develop [more effective and durable] treatment strategies. It's like navigating a desert where the landscape is constantly shifting, requiring adaptability and innovation to find the best path forward.

Dr.Camel's Conclusion

This review article provides a comprehensive overview of the current state of knowledge regarding METex14 skipping mutations in NSCLC. It's like a journey through a desert, where each new discovery leads to a deeper understanding of the landscape and the potential for new oases of hope.

Date :
  1. Date Completed 2021-11-01
  2. Date Revised 2022-07-01
Further Info :

Pubmed ID

34425853

DOI: Digital Object Identifier

PMC8381548

Related Literature

Article Analysis
・Effects of capmatinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.